Niraparib in ovarian cancer: results to date and clinical potential

Therapeutic Advances in Medical Oncology
Davide CarusoFederica Tomao

Abstract

Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enzymes involved in the base excision repair (BER) system. The introduction of inhibitors of PARP in patients with BRCA-mutated ovarian cancer is correlated with the concept of synthetic lethality. Among the PARP inhibitors introduced in clinical practice, niraparib showed interesting results in a phase III trial in the setting of maintenance treatment in ovarian cancer, after platinum-based chemotherapy. Interestingly, was niraparib showed to be efficacious not only in BRCA-mutated patients, but also in patients with other alterations of the homologous recombination (HR) system and in patients with unknown alterations. These results position niraparib as the first PARP-inhibitor with clinically and statistically significant results also in patients with no alterations in BRCA 1/2 and other genes involved in the DNA repair system. Even if the results are potentially practice-changing, the action of niraparib must be further studied and ...Continue Reading

References

Aug 1, 1989·British Journal of Obstetrics and Gynaecology·J H Shepherd
Apr 24, 1999·Biochimie·F DantzerG de Murcia
Jun 11, 1999·The Journal of Biological Chemistry·J C AméG de Murcia
Apr 2, 1963·Biochemical and Biophysical Research Communications·P CHAMBONP MANDEL
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Feb 9, 2006·Chemical Reviews·Patrick J O'Brien
Dec 7, 2006·Journal of the National Cancer Institute·Harvey A RischSteven A Narod
Sep 28, 2007·Anti-cancer Agents in Medicinal Chemistry·Tomasz Zaremba, Nicola Jane Curtin
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan Ashworth
Dec 17, 2008·Annals of the New York Academy of Sciences·Shaida A AndrabiValina L Dawson
Oct 23, 2009·Nature·Stephen P Jackson, Jiri Bartek
Mar 25, 2011·BMC Medical Genomics·Shih-Yi ChaoWoan-Shan Chang
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Jul 7, 2011·Nature Structural & Molecular Biology·William K Holloman
Dec 7, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Nasim MavaddatUNKNOWN Consortium of Investigators of Modifiers of BRCA1/2
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Jul 14, 2012·Current Medicinal Chemistry·D DavarH Tawbi
Oct 30, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S De SummaS Tommasi
Nov 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathryn P PenningtonElizabeth M Swisher
Dec 10, 2013·The Lancet Oncology·Roberta De AngelisUNKNOWN EUROCARE-5 Working Group
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junzo HamanishiIkuo Konishi
Mar 10, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melinda L TelliAndrea L Richardson
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators

❮ Previous
Next ❯

Citations

Jun 21, 2018·Cancer Biology & Therapy·Laurence BoothPaul Dent
Jan 24, 2019·Journal of Cellular and Molecular Medicine·Xuan JiangZhenyu Zhang
Jun 18, 2019·Therapeutic Advances in Medical Oncology·Jonathan A Ledermann, Eric Pujade-Lauraine
Jul 1, 2020·Frontiers in Oncology·Elisena FranzeseMichele Orditura
Jul 13, 2020·BJOG : an International Journal of Obstetrics and Gynaecology·Q LinJ Tong
Aug 20, 2019·Current Medicinal Chemistry·Maria Grazia PerroneAntonio Scilimati

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
biopsies

Clinical Trials Mentioned

NCT01294735
NCT01110603
NCT01227941
NCT01226901
NCT01847274
NCT02354131
NCT02655016
NCT02354586
NCT02657889
NCT00749502

Software Mentioned

BRACAnalysis

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Risk Factors

Breast cancer is a multifactorial disease that is influenced by both environmental and genetic factors. Discover the latest research on the environmental and genetic risk factors for breast cancer here.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.